07:22 AM EDT, 07/07/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Monday the US Food and Drug Administration approved its drug Ekterly, which is intended for treating acute attacks of hereditary angioedema in patients aged 12 and above.

Shares of the company rose more than 12% in premarket activity Monday.

The company said the approval is based on the results of a phase 3 trial demonstrating that the drug significantly accelerated symptom relief, reduced attack severity and improved resolution, compared with placebo.

KalVista said it will launch Ekterly immediately in the US, with prescriptions available starting today.

The company said it has also introduced KalVista Cares, a patient support program offering personalized services such as insurance navigation, access assistance, and treatment guidance.

Price: 13.50, Change: +1.52, Percent Change: +12.69